Characteristics and treatment pathways of patients with COPD receiving a long-acting muscarinic antagonist/long-acting ß2-agonist (LABA/LAMA) in the UK
G. Requena (Brentford, Middlesex, United Kingdom), V. Banks (Bollington, Cheshire, United Kingdom), A. Czira (Brentford, Middlesex, United Kingdom), R. Wood (Bollington, Cheshire, United Kingdom), T. Tritton (Bollington, Cheshire, United Kingdom), E. Ha (Bollington, Cheshire, United Kingdom), R. Wild (Bollington, Cheshire, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), A. Ismaila (Pennsylvania, PA, United States of America)
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Session: Inhaled treatments for COPD: real-world data
Session type: E-poster
Number: 2403
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Requena (Brentford, Middlesex, United Kingdom), V. Banks (Bollington, Cheshire, United Kingdom), A. Czira (Brentford, Middlesex, United Kingdom), R. Wood (Bollington, Cheshire, United Kingdom), T. Tritton (Bollington, Cheshire, United Kingdom), E. Ha (Bollington, Cheshire, United Kingdom), R. Wild (Bollington, Cheshire, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), A. Ismaila (Pennsylvania, PA, United States of America). Characteristics and treatment pathways of patients with COPD receiving a long-acting muscarinic antagonist/long-acting ß2-agonist (LABA/LAMA) in the UK. 2403
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2 -agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Retrospective study on the use of LABA/LAMA therapy (long acting bronchodilator agent/long acting muscarinic agent) in patients with severe COPD at first diagnosis. Source: International Congress 2019 – COPD treatment: cohorts and real-world studies Year: 2019
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Safety and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Tiotropium bromide (TIO) reduces hospitalizations in patients with COPD who had been refractory to treatment with combined inhaled corticosteroid/long acting beta agonist (ICS/LABA) Source: Eur Respir J 2005; 26: Suppl. 49, 717s Year: 2005
Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008
Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017
Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015